Bank of New York Mellon
DNTH icon

Bank of New York Mellon’s Dianthus Therapeutics DNTH Stock Holding History

Bank of New York Mellon’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25M Buy
256,393
+67,981
+36% +$5.94M ﹤0.01% 1488
2026
Q1 		$15.8M Buy
188,412
+113,280
+151% +$6.56M ﹤0.01% 1672
2025
Q4 		$3.1M Buy
75,132
+12,702
+20% +$492K ﹤0.01% 2600
2025
Q3 		$2.46M Sell
62,430
-4,282
-6% -$109K ﹤0.01% 2695
2025
Q2 		$1.24M Sell
66,712
-6,926
-9% -$130K ﹤0.01% 3002
2025
Q1 		$1.34M Buy
73,638
+748
+1% +$16.5K ﹤0.01% 2889
2024
Q4 		$1.59M Sell
72,890
-125
-0.2% -$3.21K ﹤0.01% 2865
2024
Q3 		$2M Sell
73,015
-7,920
-10% -$221K ﹤0.01% 2742
2024
Q2 		$2.09M Buy
80,935
+72,509
+861% +$1.74M ﹤0.01% 2770
2024
Q1 		$253K Buy
+8,426
New +$183K ﹤0.01% 3853
2023
Q3 		– Sell
-3,775
Closed -$45.8K – 4362
2023
Q2 		$45.8K Sell
3,775
-308
-8% -$3.5K ﹤0.01% 4190
2023
Q1 		$51.9K Buy
4,083
+3,080
+307% +$34.1K ﹤0.01% 4191
2022
Q4 		$6.34K Sell
1,003
-2
-0.2% -$35 ﹤0.01% 4441
2022
Q3 		$23K Hold
1,005
– – ﹤0.01% 4435
2022
Q2 		$19K Sell
1,005
-4,324
-81% -$107K ﹤0.01% 4499
2022
Q1 		$247K Sell
5,329
-3
-0.1% -$164 ﹤0.01% 4122
2021
Q4 		$378K Buy
5,332
+101
+2% +$10.2K ﹤0.01% 3964
2021
Q3 		$609K Buy
5,231
+267
+5% +$31.1K ﹤0.01% 3692
2021
Q2 		$777K Buy
4,964
+809
+19% +$149K ﹤0.01% 3561
2021
Q1 		$788K Sell
4,155
-77
-2% -$13K ﹤0.01% 3468
2020
Q4 		$531K Buy
4,232
+138
+3% +$15.6K ﹤0.01% 3588
2020
Q3 		$446K Sell
4,094
-69
-2% -$8.18K ﹤0.01% 3551
2020
Q2 		$500K Buy
4,163
+244
+6% +$34.4K ﹤0.01% 3475
2020
Q1 		$394K Sell
3,919
-10
-0.3% -$1.85K ﹤0.01% 3487
2019
Q4 		$953K Buy
3,929
+186
+5% +$34.8K ﹤0.01% 3271
2019
Q3 		$614K Buy
3,743
+436
+13% +$82.8K ﹤0.01% 3424
2019
Q2 		$781K Buy
3,307
+624
+23% +$154K ﹤0.01% 3364
2019
Q1 		$707K Buy
2,683
+1,698
+172% +$293K ﹤0.01% 3379
2018
Q4 		$90K Buy
+985
New +$134K ﹤0.01% 3978

Other funds holding DNTH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Bank of New York Mellon's DNTH Position: Q2 2026 in Review

Bank of New York Mellon increased its Dianthus Therapeutics (DNTH) stake by 36% in Q2 2026, buying an estimated $5.94M and bringing the position to 256,393 shares worth $25M. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

Bank of New York Mellon first reported a position in DNTH in Q4 2018 and has held it in 29 quarters since. 84 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Bank of New York Mellon held 256,393 shares of Dianthus Therapeutics worth $25M as of Q2 2026.
  • Bank of New York Mellon bought 67,981 Dianthus Therapeutics shares in Q2 2026, an estimated $5.94M.
  • Dianthus Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1488 holding.
  • Bank of New York Mellon first reported a position in Dianthus Therapeutics in Q4 2018 and has held it in 29 quarters since.
  • 84 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.